All companies
Visit website
KOIOS MEDICAL, INC
OperatingKoios Medical, Inc.
Healthcare · Founded 2011
AI-powered software diagnosing cancer. Super human accuracy
Post-money valuation ⓘ
$61.3M
As of Nov 2024 · from KOIOS MEDICAL, INC Preferred Stock 1 · pre-money + amount raised, not a traded price
Total raised
$4,014,526
Across 2 rounds since 2024
Latest share price
$4.6998
Reg CF Offering (2025) offering price
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its source$50K
−$5.6M
2022
$293K
−$5.6M
2023
$637K
−$4.8M
2024
$1.6M
−$2.7M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$49,911
$293,350
$637,331
$1,620,593
Cost of goods sold
$189,738
$71,355
$267,049
$293,128
Gross margin
-280%
76%
58%
82%
Net income
-$5,600,235
-$5,571,268
-$4,761,652
-$2,687,228
Taxes paid
$5,228
$1,934
$0
$0
Balance sheet
Cash
$1,193,518
$2,123,822
$46,425
$168,058
Accounts receivable
$49,579
$31,750
$103,563
$322,821
Total assets
$1,466,393
$2,465,729
$369,719
$753,413
Short-term debt
$6,339,259
$934,027
$1,968,362
$1,766,418
Long-term debt
$0
$0
$0
$988,702
Total liabilities
$6,339,259
$934,027
$1,968,362
$2,755,120
Other
Headcount
—
20
17
12
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$61.3M
post-money
KOIOS MEDICAL, INC Preferred Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $1.3M / $500MInvestors 447Post-money $61.3M
Reg CF annual-report compliance
Compliant
Filed 2 of 2 annual reports (FY2024–FY2025)
818 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 15 filings on EDGARSource: ManualCIK 0001764417Share price $4.6998
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.